Company Overview and News
Good day and welcome to the Hope Bancorp Third Quarter 2018 Earnings Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today’s presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note this event is being recorded.
The following slide deck was published by Hope Bancorp, Inc. in conjunction with their 2018 Q3 earnings call.
Wall Street expects a year-over-year increase in earnings on higher revenues when Hope Bancorp (HOPE - Free Report) reports results for the quarter ended September 2018. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.
2018-10-05 zacks - 1
Whether it's through stocks, bonds, ETFs, or other types of securities, all investors love seeing their portfolios score big returns. But when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments.
HOPE WBA LMAT YY
The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks.
HOPE WBA LMAT YY
Investors interested in stocks from the Banks - West sector have probably already heard of Hope Bancorp (HOPE - Free Report) and Columbia Banking (COLB - Free Report) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.
Investors looking for stocks in the Banks - West sector might want to consider either Hope Bancorp (HOPE - Free Report) or Columbia Banking (COLB - Free Report) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.
HOPE TXN MDPEB MDP
Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor's dream. But when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments.
HOPE MDPEB MDP
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
HOPE MDPEB MDP
2018-08-13 seekingalpha - 1
HAFC is a $5.4 billion-asset bank serving “multi-ethnic communities” through 40 full-service branches and 9 loan production offices in California, Texas, Illinois, Virginia, New Jersey, New York, Colorado, Washington and Georgia.
WFC BAC HAFC CATY HOPE JPM EWBC CATYW
BBCN Bancorp Inc. (NASDAQ:BBCN) has 203 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 125,393,593 shares. Largest shareholders include BlackRock Inc., Vanguard Group Inc, BlackRock Fund Advisors, Dimensional Fund Advisors Lp, Fuller & Thaler Asset Management, Inc., Price T Rowe Associates Inc /md/, State Street Corp, Lsv Asset Management, BlackRock Institutional Trust Company, N.
STT HOPE NTRSP BBCN CGC TWMJF BLK NTRS WEED
The following slide deck was published by Hope Bancorp, Inc. in conjunction with their 2018 Q2 earnings call.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to HOPE / Hope Bancorp, Inc. on message board site Silicon Investor.
as of ET